• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.

作者信息

Skrabs C, Müller C, Agis H, Mannhalter C, Jäger U

出版信息

Leukemia. 2002 Sep;16(9):1884-6. doi: 10.1038/sj.leu.2402567.

DOI:10.1038/sj.leu.2402567
PMID:12200717
Abstract
摘要

相似文献

1
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.利妥昔单抗联合CHOP方案治疗乙肝病毒携带的淋巴瘤患者：一项诊断与治疗挑战
Leukemia. 2002 Sep;16(9):1884-6. doi: 10.1038/sj.leu.2402567.
2
Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.既往乙肝已缓解的淋巴瘤患者在接受含或不含利妥昔单抗的抗癌治疗过程中发生的乙肝病毒再激活。
J Clin Oncol. 2009 Feb 1;27(4):605-11. doi: 10.1200/JCO.2008.18.0182. Epub 2008 Dec 15.
3
Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.利妥昔单抗联合环磷酰胺/阿霉素/长春新碱/泼尼松（CHOP）治疗干燥综合征相关B细胞侵袭性非霍奇金淋巴瘤。
Rheumatology (Oxford). 2004 Aug;43(8):1050-3. doi: 10.1093/rheumatology/keh248. Epub 2004 Jun 8.
4
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.老年弥漫性大B细胞淋巴瘤患者中，CHOP化疗联合利妥昔单抗与单纯CHOP化疗的比较。
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
5
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松进行免疫化疗可显著提高反应率并延长至治疗失败时间，但对既往未治疗的套细胞淋巴瘤患者的长期预后无改善：德国低度淋巴瘤研究组（GLSG）一项前瞻性随机试验的结果
J Clin Oncol. 2005 Mar 20;23(9):1984-92. doi: 10.1200/JCO.2005.08.133. Epub 2005 Jan 24.
6
Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.乙肝表面抗原阴性/乙肝核心抗体阳性患者接受利妥昔单抗联合化疗而未常规进行抗病毒预防时乙型肝炎病毒（HBV）再激活的风险。
Ann Hematol. 2011 Oct;90(10):1219-23. doi: 10.1007/s00277-011-1241-0. Epub 2011 Apr 26.
7
CHOP plus rituximab--balancing facts and opinion.环磷酰胺、阿霉素、长春新碱、强的松联合利妥昔单抗——权衡事实与观点。
N Engl J Med. 2002 Jan 24;346(4):280-2. doi: 10.1056/NEJM200201243460411.
8
Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.在接受利妥昔单抗联合CHOP治疗的淋巴瘤患者中，停用抢先使用的拉米夫定后出现的迟发性乙型肝炎病毒再激活。
Ann Hematol. 2004 Dec;83(12):769-74. doi: 10.1007/s00277-004-0899-y. Epub 2004 Aug 25.
9
Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.在接受CHOP化疗加利妥昔单抗治疗后，一名表面抗原和乙肝DNA均为阴性的弥漫性大B细胞淋巴瘤患者发生暴发性乙型肝炎。
Leuk Lymphoma. 2007 Feb;48(2):431-3. doi: 10.1080/10428190601059704.
10
Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.利妥昔单抗与含蒽环类化疗药物联合治疗老年原发性皮肤大B细胞淋巴瘤（腿部型）。
Arch Dermatol. 2010 Jan;146(1):89-91. doi: 10.1001/archdermatol.2009.345.

引用本文的文献

1
Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.嵌合抗原受体-T 细胞治疗人源化抗 CD19 对慢性和已解决乙型肝炎病毒感染的淋巴瘤和白血病患者安全且有效。
Hematol Oncol. 2021 Feb;39(1):75-86. doi: 10.1002/hon.2807. Epub 2020 Oct 1.
2
Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.风湿性疾病患者隐匿性乙型肝炎病毒感染的再激活：发病机制、风险评估及预防
Rheumatol Int. 2016 May;36(5):635-41. doi: 10.1007/s00296-015-3395-x. Epub 2015 Nov 16.
3
Hepatitis B virus reactivation with a rituximab-containing regimen.
含利妥昔单抗方案导致的乙型肝炎病毒再激活。
World J Hepatol. 2015 Sep 28;7(21):2344-51. doi: 10.4254/wjh.v7.i21.2344.
4
Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.利妥昔单抗治疗的非霍奇金淋巴瘤患者中乙肝病毒表面抗原反向血清学转换的风险：一项大型队列回顾性研究
Medicine (Baltimore). 2015 Aug;94(32):e1321. doi: 10.1097/MD.0000000000001321.
5
Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.在达沙替尼治疗慢性髓性白血病期间，乙肝病毒免疫逃逸突变体G145R导致已缓解感染的重新激活。
Int J Hematol. 2015 Sep;102(3):379-82. doi: 10.1007/s12185-015-1788-y. Epub 2015 Apr 5.
6
Hepatitis B virus reactivation with rituximab-containing regimen.含利妥昔单抗方案导致的乙型肝炎病毒再激活。
World J Hepatol. 2013 Nov 27;5(11):612-20. doi: 10.4254/wjh.v5.i11.612.
7
Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.乙肝病毒感染对接受或未接受利妥昔单抗治疗的弥漫性大B细胞淋巴瘤的临床分析及预后意义
Exp Ther Med. 2013 Jul;6(1):109-114. doi: 10.3892/etm.2013.1079. Epub 2013 Apr 25.
8
Rituximab administration and reactivation of HBV.利妥昔单抗的使用与乙肝病毒再激活
Hepat Res Treat. 2010;2010:182067. doi: 10.1155/2010/182067. Epub 2010 Dec 1.
9
A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma.利妥昔单抗联合 CHOP 方案治疗弥漫性大 B 细胞淋巴瘤致拉米夫定敏感的新发急性乙型肝炎 1 例
Hepatol Int. 2009 Mar;3(1):316-22. doi: 10.1007/s12072-008-9094-x. Epub 2008 Sep 23.
10
Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤中乙型肝炎病毒感染的临床及预后分析
BMC Cancer. 2008 Apr 23;8:115. doi: 10.1186/1471-2407-8-115.